Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults
研究概览
详细说明
In the United States, yearly influenza vaccination begins in August or September. However, influenza season can extend into April of the following year. The duration of protection from annual vaccination in older adults is unknown, and little is known about factors associated with the maintenance of response throughout the influenza season. This study evaluated factors associated with the immune response of older adults to trivalent influenza vaccine and the maintenance of antibody responses for the duration of the influenza season.
Subjects
Subjects were enrolled at two sites, Vanderbilt University Medical Center (Nashville, TN) and Marshfield Clinic Research Foundation (Marshfield, WI), during September and October 2009. Subjects were eligible for recruitment if they were ≥50 years of age and had no contraindication to influenza vaccination. Subject recruitment included advertisements at Vanderbilt University Medical Center and letters of invitation to older adults who had received an influenza vaccine in the year prior at Marshfield Clinic.1 All subjects were vaccinated either by their usual caregiver or by the study staff. Strain components for the 2009-2010 Northern Hemisphere vaccine included A/Brisbane/59/2007-like (H1N1), A/Brisbane/10/2007-like (H3N2), and B/Brisbane/60/2008-like. Participants were given the trivalent seasonal vaccine because the 2009 H1N1 pandemic vaccine was not available.
Data Collection
All subjects donated serum pre-vaccination (S1) during September through October 2009, 21 - 28 days post-vaccination (S2) and post-influenza season, May through July, 2010, approximately 250 days (8 months) post-vaccination (S3). Study procedures, informed consent documents and data collection forms were reviewed and approved by Institutional Review Boards at each of the study sites.
Age, co-morbid conditions, sex, and race were ascertained from participant interview. Recent chemotherapy, radiation therapy, or use of immunomodulating medications were ascertained by self-report or chart review. CDC-defined high risk medical conditions were identified by self-report of organ transplantation, cancer, diabetes mellitus, splenectomy (functional or anatomic), cardiovascular disease, renal disease, sickle cell disease, chronic pulmonary disease, seizure disorder, immune deficiency, or dementia.2 Self-reported stress was determined by asking participants to respond yes or no to the question "Have you suffered psychological stress or acute disease in the past 3 months?" included as part of the Mini Nutritional Assessment Questionnaire.3 Height and weight were measured by research study staff and body mass index (BMI) was calculated as weight (kg) / height (m)2.
Laboratory Methods
Blood samples were processed, stored, and shipped by each institution's local Sample Processing Core to Battelle (Columbus, OH). Hemagglutinin inhibition (HAI) testing was performed in duplicate against the influenza vaccine strains in the 2009-2010 Northern Hemisphere influenza vaccine. Although there is debate about the best correlate of protection for influenza,4 seroprotection was defined as an HAI titer of ≥40 since it is the correlate recognized by the United States Food and Drug Administration.5 Seroconversion was measured at S2 and defined as a four-fold rise in HAI post-influenza vaccination compared to pre-vaccination or ≥40 if S1 was <10. Maintenance of antibody response was measured in participants with an S2 ≥40, and defined as an S3≥40. If duplicate HAI results were discrepant by more than two fold, a third test was performed and the minimum result was recorded.
Statistical Analysis
Multivariable logistic regression models were run for the binary outcomes seroprotection at S2 and S3 and seroconversion at S2. Age, BMI, stress, high risk medical conditions (yes/no), female gender, study site and transformed S1 titer were included in all models. Time in days from S1 to S3 was included in models with S3 related outcomes as a continuous variable. Restricted cubic splines were applied to age and BMI. All raw HAI titers were log transformed using the method outlined by Beyer,6 changing dilution titers to integers with HAI <10 coded as 0, 10 as 1, 20 as 2, 40 as 3 and so on. Interaction terms between age and high risk status, and stress or age and sex were tested and were not included based on non-significant p values of overall interaction terms. Figures were generated by predicting the probability of having a HAI titer ≥40 by logistic regression. All analyses were done using R version 2.12.2.
研究类型
注册 (实际的)
参与标准
资格标准
适合学习的年龄
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Age >=50 years
Exclusion Criteria:
- Prior vaccine allergy or history of guillain barre
学习计划
研究是如何设计的?
设计细节
- 观测模型:队列
- 时间观点:预期
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Maintenance of Immune Response using Hemagglutinin inhibition titers
大体时间:1 year
|
1 year
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
Influenza Vaccine的临床试验
-
QIAGEN Gaithersburg, Inc完全的呼吸道合胞病毒感染 | 甲型流感 | 鼻病毒 | 乙型流感 | QIAGEN ResPlex II Advanced Panel | 人类副流感病毒 1 引起的感染 | 副流感 2 型 | 3 型副流感 | 副流感 4 型 | 人类偏肺病毒 A/B | 柯萨奇病毒/埃可病毒 | B/C/E 型腺病毒 | 冠状病毒亚型 229E | 冠状病毒亚型 NL63 | 冠状病毒亚型 OC43 | 冠状病毒亚型 HKU1 | 人类博卡病毒 | Artus 流感 A/B RT-PCR 检测美国
-
Erasme University HospitalRoche Diagnostics; LHUB-ULB终止
-
SENAI CIMATEC招聘中
-
Federal Budgetary Research Institution State Research...完全的